CN1088064C - 萘并噁嗪衍生物、其制备方法及含有它们的药物组合物 - Google Patents

萘并噁嗪衍生物、其制备方法及含有它们的药物组合物 Download PDF

Info

Publication number
CN1088064C
CN1088064C CN98119987A CN98119987A CN1088064C CN 1088064 C CN1088064 C CN 1088064C CN 98119987 A CN98119987 A CN 98119987A CN 98119987 A CN98119987 A CN 98119987A CN 1088064 C CN1088064 C CN 1088064C
Authority
CN
China
Prior art keywords
compound
formula
trans
naphtho
hexahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98119987A
Other languages
English (en)
Chinese (zh)
Other versions
CN1222516A (zh
Inventor
J－L·佩吉里恩
J－C·哈曼杰
M·米兰
F·莱杰尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN1222516A publication Critical patent/CN1222516A/zh
Application granted granted Critical
Publication of CN1088064C publication Critical patent/CN1088064C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN98119987A 1997-09-01 1998-08-31 萘并噁嗪衍生物、其制备方法及含有它们的药物组合物 Expired - Fee Related CN1088064C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9710852 1997-09-01
FR9710852A FR2767825A1 (fr) 1997-09-01 1997-09-01 Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CN1222516A CN1222516A (zh) 1999-07-14
CN1088064C true CN1088064C (zh) 2002-07-24

Family

ID=9510643

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98119987A Expired - Fee Related CN1088064C (zh) 1997-09-01 1998-08-31 萘并噁嗪衍生物、其制备方法及含有它们的药物组合物

Country Status (18)

Country Link
US (1) US6025356A (cg-RX-API-DMAC7.html)
EP (1) EP0899267B1 (cg-RX-API-DMAC7.html)
JP (1) JP4417451B2 (cg-RX-API-DMAC7.html)
CN (1) CN1088064C (cg-RX-API-DMAC7.html)
AT (1) ATE229513T1 (cg-RX-API-DMAC7.html)
AU (1) AU740928C (cg-RX-API-DMAC7.html)
BR (1) BR9803933A (cg-RX-API-DMAC7.html)
CA (1) CA2246482C (cg-RX-API-DMAC7.html)
DE (1) DE69810034T2 (cg-RX-API-DMAC7.html)
DK (1) DK0899267T3 (cg-RX-API-DMAC7.html)
ES (1) ES2189108T3 (cg-RX-API-DMAC7.html)
FR (1) FR2767825A1 (cg-RX-API-DMAC7.html)
HU (1) HU226059B1 (cg-RX-API-DMAC7.html)
NO (1) NO311218B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ331637A (cg-RX-API-DMAC7.html)
PL (1) PL194533B1 (cg-RX-API-DMAC7.html)
PT (1) PT899267E (cg-RX-API-DMAC7.html)
ZA (1) ZA987963B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1534679A4 (en) * 2002-08-30 2007-06-06 Biostratum Inc INHIBITORS OF POST-AMADORI ADVANCED GLYCATION ENDPRODUCTS
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
FR2906249B1 (fr) * 2006-09-26 2008-12-19 Servier Lab Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2098511A1 (en) 2008-03-07 2009-09-09 Solvias AG Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring
WO2009156458A1 (en) * 2008-06-27 2009-12-30 H. Lundbeck A/S Novel phenolic and catecholic amines and prodrugs thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019719A1 (en) * 1990-06-15 1991-12-26 Whitby Research, Inc. Substituted naphthoxazines useful as dopaminergics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
US4540691A (en) * 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019719A1 (en) * 1990-06-15 1991-12-26 Whitby Research, Inc. Substituted naphthoxazines useful as dopaminergics

Also Published As

Publication number Publication date
ES2189108T3 (es) 2003-07-01
HU9801951D0 (en) 1998-11-30
DE69810034T2 (de) 2003-08-14
HK1020340A1 (en) 2000-04-14
PL194533B1 (pl) 2007-06-29
HUP9801951A2 (hu) 2000-02-28
FR2767825A1 (fr) 1999-03-05
HUP9801951A3 (en) 2000-04-28
CN1222516A (zh) 1999-07-14
JP4417451B2 (ja) 2010-02-17
HU226059B1 (en) 2008-04-28
DK0899267T3 (da) 2003-03-10
NO984007L (no) 1999-03-02
PL328285A1 (en) 1999-03-15
JPH11130759A (ja) 1999-05-18
CA2246482A1 (fr) 1999-03-01
AU8302498A (en) 1999-03-11
EP0899267B1 (fr) 2002-12-11
BR9803933A (pt) 2001-04-24
NO311218B1 (no) 2001-10-29
NO984007D0 (no) 1998-08-31
ATE229513T1 (de) 2002-12-15
AU740928B2 (en) 2001-11-15
ZA987963B (en) 1999-03-04
PT899267E (pt) 2003-04-30
CA2246482C (fr) 2002-11-26
NZ331637A (en) 1999-07-29
US6025356A (en) 2000-02-15
DE69810034D1 (de) 2003-01-23
AU740928C (en) 2002-05-16
EP0899267A1 (fr) 1999-03-03

Similar Documents

Publication Publication Date Title
US5652246A (en) Piperidine compounds
CA2428039C (en) Serotonergic agents
IL92990A (en) Piperazinyl butyl indole derivatives, process for their preparation and pharmaceutical compositions containing them
CN1720232A (zh) 汉防己碱和汉防己碱化合物,合成和应用
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
EP1096926B1 (en) Methods and compounds for treating depression
US4139634A (en) Indole derivatives and process for preparing the same
CN1122666C (zh) 新的2,3－二氢化茚醇化合物,其制备方法和包含它们的药物组合物
JP4417451B2 (ja) 新規な二置換ｔｒａｎｓ−３，４，４ａ，５，６，１０ｂ−ヘキサヒドロ−２Ｈ−ナフト〔１，２−ｂ〕−１，４−オキサジン、それらの製造方法及びそれらを含有する医薬組成物
JPH11130759A5 (cg-RX-API-DMAC7.html)
AU780027B2 (en) New indenoindolone compounds, a process for their preparation and pharmaceutical compositions containing them
HK1020340B (en) New disubstituted trans-3,4,4a,5,6,10b-hexahydro-2h-naphth (1,2-b)-1,4-oxazines, a process for their preparation and pharmaceutical compositions containing them
CN1050358C (zh) 新四环哌嗪和1,4-噁嗪化合物,其制备和药物组合物
US5530002A (en) 1-[2-(1H-inden-3-yl)ethyl]-4-(naphth-1-yl)piperazine derivatives, their preparation and their application in therapeutics
JPS60202887A (ja) ジアゼピノインドール類、その製造法および医薬
EP1905775B1 (fr) Composés tétracycliques, leur procédé de préparation, les compositions pharmaceutiques qui les contiennent et leur utilisation comme ligands des récepteurs dopaminergiques.
JPH01165588A (ja) ５，６，７，８‐テトラハイドロ‐４ｈ‐イソオキサゾロ〔４，５‐ｃ〕アゼピン誘導体、異性体およびそれらの酸付加塩
HK1057864B (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
JP2010031063A (ja) 医薬組成物
CZ205299A3 (cs) Diazospiro[3,5]nonanové deriváty

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020724

Termination date: 20120831